Novo Nordisk Gets FDA Approval For Fast-Acting Insulin

On September 29, the FDA approved Novo-Nordisk’s (NVO) new drug to treat diabetes. Fiasp is fast-acting insulin that controls post-meal spikes in blood sugar. It works faster than existing drugs on the market and is already approved in both Canada and Europe.

 

Sonal caught the news and sent an alert at 11:03 am. The next trade was at $47.93.

The price climbed throughout the day and closed at $48.15. Over the next four days, NVO continued to trade above $48.75. Investors had plenty of time to profit from the September 29 event.

 

Visit the Knowledge Center to learn more about trading clinical trials.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!